CN101878216B - 作为蛋白激酶抑制剂的嘧啶衍生物 - Google Patents
作为蛋白激酶抑制剂的嘧啶衍生物 Download PDFInfo
- Publication number
- CN101878216B CN101878216B CN2008801182902A CN200880118290A CN101878216B CN 101878216 B CN101878216 B CN 101878216B CN 2008801182902 A CN2008801182902 A CN 2008801182902A CN 200880118290 A CN200880118290 A CN 200880118290A CN 101878216 B CN101878216 B CN 101878216B
- Authority
- CN
- China
- Prior art keywords
- compound
- methyl
- amino
- cyclopentyl
- diaza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- SBYHFKPVCBCYGV-UHFFFAOYSA-N C(C1)C2CCN1CC2 Chemical compound C(C1)C2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- ONIVTPSMIVIGHU-UHFFFAOYSA-N CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(N)=O)c1)c1OC)nc1)c1N1C)C1=O Chemical compound CC(C)(CN(C1CCCC1)c(nc(Nc(ccc(C(N)=O)c1)c1OC)nc1)c1N1C)C1=O ONIVTPSMIVIGHU-UHFFFAOYSA-N 0.000 description 1
- QYWMDSSWIGWXSE-UHFFFAOYSA-N CC(C1)N(C2CCCC2)c(nc(Nc(cc2)ccc2C(O)=O)nc2)c2NC1=O Chemical compound CC(C1)N(C2CCCC2)c(nc(Nc(cc2)ccc2C(O)=O)nc2)c2NC1=O QYWMDSSWIGWXSE-UHFFFAOYSA-N 0.000 description 1
- KZLQLABUFJNPSZ-UHFFFAOYSA-N CC(C1)N(C2CCCC2)c(nc(Nc(ccc(C(NC2CCN(C)CC2)=O)c2)c2OC)nc2)c2N(C)C1=O Chemical compound CC(C1)N(C2CCCC2)c(nc(Nc(ccc(C(NC2CCN(C)CC2)=O)c2)c2OC)nc2)c2N(C)C1=O KZLQLABUFJNPSZ-UHFFFAOYSA-N 0.000 description 1
- YAMIMLRPPHTJPC-UHFFFAOYSA-N CC(CN(C1CCCC1)c(nc(nc1)Cl)c1[N+]([O-])=O)C(OC)=O Chemical compound CC(CN(C1CCCC1)c(nc(nc1)Cl)c1[N+]([O-])=O)C(OC)=O YAMIMLRPPHTJPC-UHFFFAOYSA-N 0.000 description 1
- CKKCYWXFAHYHMM-UHFFFAOYSA-N CCC(CC)N(CC1)c2nc(Nc(c(OC)c3)ccc3C(NC3CCN(C)CC3)=O)ncc2N(CC)C1=O Chemical compound CCC(CC)N(CC1)c2nc(Nc(c(OC)c3)ccc3C(NC3CCN(C)CC3)=O)ncc2N(CC)C1=O CKKCYWXFAHYHMM-UHFFFAOYSA-N 0.000 description 1
- GPXQMZVGHFRABO-UHFFFAOYSA-N CN(CC1)CCN1NC(c(cc1)cc(F)c1Nc(nc1)nc(N(CC23CC2)C2CCCC2)c1N(C)C3=O)=O Chemical compound CN(CC1)CCN1NC(c(cc1)cc(F)c1Nc(nc1)nc(N(CC23CC2)C2CCCC2)c1N(C)C3=O)=O GPXQMZVGHFRABO-UHFFFAOYSA-N 0.000 description 1
- PEXIBZBONDDAHU-UHFFFAOYSA-N CN(c(cn1)c(N(CC2)C3CCOCC3)nc1Cl)C2=O Chemical compound CN(c(cn1)c(N(CC2)C3CCOCC3)nc1Cl)C2=O PEXIBZBONDDAHU-UHFFFAOYSA-N 0.000 description 1
- UHCROXCVKZSKQH-UHFFFAOYSA-N COc1cc(C(O)=O)ccc1Nc(nc1)nc(N(CC2)C3CCCCC3)c1NC2=O Chemical compound COc1cc(C(O)=O)ccc1Nc(nc1)nc(N(CC2)C3CCCCC3)c1NC2=O UHCROXCVKZSKQH-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0719038.2 | 2007-09-28 | ||
GB0719038A GB0719038D0 (en) | 2007-09-28 | 2007-09-28 | Compound |
GB0806844A GB0806844D0 (en) | 2008-04-15 | 2008-04-15 | Compound |
GB0806844.7 | 2008-04-15 | ||
PCT/GB2008/003305 WO2009040556A1 (en) | 2007-09-28 | 2008-09-29 | Pyrimidine derivatives as protein kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101878216A CN101878216A (zh) | 2010-11-03 |
CN101878216B true CN101878216B (zh) | 2013-07-10 |
Family
ID=40199600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008801182902A Active CN101878216B (zh) | 2007-09-28 | 2008-09-29 | 作为蛋白激酶抑制剂的嘧啶衍生物 |
Country Status (10)
Country | Link |
---|---|
US (3) | US8563542B2 (pt-PT) |
EP (2) | EP2610256B1 (pt-PT) |
JP (2) | JP5410432B2 (pt-PT) |
CN (1) | CN101878216B (pt-PT) |
CA (1) | CA2700979C (pt-PT) |
ES (2) | ES2457394T3 (pt-PT) |
HK (2) | HK1146042A1 (pt-PT) |
PL (2) | PL2610256T3 (pt-PT) |
RU (2) | RU2478100C2 (pt-PT) |
WO (1) | WO2009040556A1 (pt-PT) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080095902A (ko) | 2006-02-14 | 2008-10-29 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제의 억제제로서 유용한 디하이드로디아제핀 |
EP2190849B1 (en) | 2007-08-15 | 2013-11-20 | Vertex Pharmceuticals Incorporated | 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases |
KR20140097440A (ko) | 2007-09-25 | 2014-08-06 | 다케다 야쿠힌 고교 가부시키가이샤 | 폴로형 키나아제 억제제 |
JP5410432B2 (ja) | 2007-09-28 | 2014-02-05 | サイクラセル リミテッド | プロテインキナーゼ阻害剤としてのピリミジン誘導体 |
MX346186B (es) | 2008-06-23 | 2017-03-10 | Vertex Pharma | Inhibidores de proteina cinasas. |
CN102076691A (zh) | 2008-06-23 | 2011-05-25 | 维泰克斯制药公司 | 蛋白激酶抑制剂 |
CN104940202B (zh) | 2009-06-17 | 2018-10-16 | 沃泰克斯药物股份有限公司 | 流感病毒复制抑制剂 |
CA2773742C (en) | 2009-09-25 | 2017-12-05 | Vertex Pharmaceuticals Incorporated | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors |
RU2012116526A (ru) | 2009-09-25 | 2013-10-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы |
JP5713367B2 (ja) | 2010-06-04 | 2015-05-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Lrrk2モジュレーターとしてのアミノピリミジン誘導体 |
CA3017869C (en) | 2010-11-10 | 2021-07-27 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
CN103492381A (zh) | 2010-12-16 | 2014-01-01 | 沃泰克斯药物股份有限公司 | 流感病毒复制的抑制剂 |
UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
GB201205752D0 (en) * | 2012-03-30 | 2012-05-16 | Cyclacel Ltd | Treatment |
US9676792B2 (en) | 2013-03-15 | 2017-06-13 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone compounds and methods of treating disorders |
RU2016105108A (ru) | 2013-07-25 | 2017-08-30 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ингибиторы факторов транскрипции и их применение |
NZ719729A (en) | 2013-11-13 | 2022-04-29 | Vertex Pharma | Inhibitors of influenza viruses replication |
PL3068782T3 (pl) | 2013-11-13 | 2018-12-31 | Vertex Pharmaceuticals Incorporated | Sposoby wytwarzania inhibitorów replikacji wirusów grypy |
KR20160115953A (ko) | 2014-01-31 | 2016-10-06 | 다나-파버 캔서 인스티튜트 인크. | 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도 |
JP2017504651A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | ジアゼパン誘導体の使用 |
KR101517414B1 (ko) * | 2014-04-24 | 2015-05-04 | 고려대학교 산학협력단 | 염증성 질환의 예방 또는 치료용 약학 조성물 |
BR112017002369A2 (pt) | 2014-08-08 | 2017-12-05 | Dana Farber Cancer Inst Inc | derivados de diazepana e usos dos mesmos |
EP3546473A1 (en) | 2014-12-16 | 2019-10-02 | Kayla Therapeutics | Cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction |
JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インフルエンザウイルスの複製の阻害剤を調製する方法 |
MA42422A (fr) | 2015-05-13 | 2018-05-23 | Vertex Pharma | Inhibiteurs de la réplication des virus de la grippe |
EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS |
SG10202007099TA (en) | 2015-09-11 | 2020-08-28 | Dana Farber Cancer Inst Inc | Acetamide thienotriazoldiazepines and uses thereof |
JP2018526421A (ja) | 2015-09-11 | 2018-09-13 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | シアノチエノトリアゾロジアゼピンおよびこれらの使用 |
WO2017066428A1 (en) | 2015-10-13 | 2017-04-20 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Brd4-kinase inhibitors as cancer therapeutics |
EP3380100A4 (en) | 2015-11-25 | 2019-10-02 | Dana-Farber Cancer Institute, Inc. | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF |
US10975092B2 (en) * | 2016-03-04 | 2021-04-13 | Anhui New Star Pharmaceutical Development Co., Ltd. | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof |
CA3020172A1 (en) * | 2016-04-07 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating pi3k-mediated disorders |
EP3704115A1 (en) | 2017-11-02 | 2020-09-09 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
JP2021501781A (ja) * | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
CN114269727A (zh) * | 2019-08-16 | 2022-04-01 | 西克拉塞尔有限公司 | 制备嘧啶并二氮杂环庚三烯衍生物的方法 |
CN114269752A (zh) * | 2019-08-16 | 2022-04-01 | 西克拉塞尔有限公司 | 嘧啶并二氮杂环庚三烯衍生物的结晶形式 |
US20220378919A1 (en) * | 2019-09-27 | 2022-12-01 | Dana-Farber Cancer Institute, Inc. | Erk5 degraders as therapeutics in cancer and inflammatory diseases |
TW202404636A (zh) | 2022-04-08 | 2024-02-01 | 美商英伊布里克斯公司 | Dr5促效劑及plk1抑制劑或cdk抑制劑之組合療法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9117635D0 (en) | 1991-08-15 | 1991-10-02 | British Telecomm | Phase shifter |
GB0302220D0 (en) | 2003-01-30 | 2003-03-05 | Cyclacel Ltd | Use |
CA2517020C (en) * | 2003-02-26 | 2012-06-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, method for the production and use thereof in the form of drugs |
US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
US8710009B2 (en) | 2004-05-26 | 2014-04-29 | The Texas A&M University System | HSP20 inhibits amyloidogenesis and neurotoxicity |
US7459448B2 (en) * | 2004-10-04 | 2008-12-02 | Millennium Pharmaceuticals, Inc. | Lactam compounds useful as protein kinase inhibitors |
DE602006012322D1 (de) | 2005-06-24 | 2010-04-01 | Lilly Co Eli | Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate |
US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
KR20080095902A (ko) * | 2006-02-14 | 2008-10-29 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제의 억제제로서 유용한 디하이드로디아제핀 |
TW200808325A (en) * | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
EP2139892B1 (en) * | 2007-03-22 | 2011-09-14 | Takeda Pharmaceutical Company Limited | Substituted pyrimidodiazepines useful as plk1 inhibitors |
KR20140097440A (ko) * | 2007-09-25 | 2014-08-06 | 다케다 야쿠힌 고교 가부시키가이샤 | 폴로형 키나아제 억제제 |
JP5410432B2 (ja) | 2007-09-28 | 2014-02-05 | サイクラセル リミテッド | プロテインキナーゼ阻害剤としてのピリミジン誘導体 |
US20090291938A1 (en) * | 2007-11-19 | 2009-11-26 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
US8710068B2 (en) | 2009-01-19 | 2014-04-29 | The Trustees Of The University Of Pennsylvania | Method of treating cancer using a survivin inhibitor |
GB201205752D0 (en) | 2012-03-30 | 2012-05-16 | Cyclacel Ltd | Treatment |
-
2008
- 2008-09-29 JP JP2010526364A patent/JP5410432B2/ja active Active
- 2008-09-29 CA CA2700979A patent/CA2700979C/en active Active
- 2008-09-29 EP EP13156251.4A patent/EP2610256B1/en active Active
- 2008-09-29 WO PCT/GB2008/003305 patent/WO2009040556A1/en active Application Filing
- 2008-09-29 PL PL13156251.4T patent/PL2610256T3/pl unknown
- 2008-09-29 RU RU2010116759/04A patent/RU2478100C2/ru active
- 2008-09-29 CN CN2008801182902A patent/CN101878216B/zh active Active
- 2008-09-29 EP EP20080806455 patent/EP2205603B1/en active Active
- 2008-09-29 ES ES08806455T patent/ES2457394T3/es active Active
- 2008-09-29 PL PL08806455T patent/PL2205603T3/pl unknown
- 2008-09-29 ES ES13156251.4T patent/ES2585110T3/es active Active
- 2008-09-29 US US12/680,353 patent/US8563542B2/en active Active
-
2010
- 2010-12-30 HK HK10112280A patent/HK1146042A1/xx unknown
- 2010-12-30 HK HK14100038.8A patent/HK1187895A1/zh unknown
-
2013
- 2013-02-26 RU RU2013108456A patent/RU2623221C2/ru active
- 2013-06-05 US US13/910,349 patent/US9133199B2/en active Active
- 2013-11-06 JP JP2013230231A patent/JP5863196B2/ja active Active
-
2015
- 2015-08-07 US US14/820,711 patent/US9493471B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2205603B1 (en) | 2014-01-15 |
HK1146042A1 (en) | 2011-05-13 |
CA2700979C (en) | 2017-06-20 |
RU2623221C2 (ru) | 2017-06-23 |
US8563542B2 (en) | 2013-10-22 |
EP2205603A1 (en) | 2010-07-14 |
PL2205603T3 (pl) | 2014-07-31 |
RU2013108456A (ru) | 2014-09-10 |
ES2585110T3 (es) | 2016-10-03 |
RU2478100C2 (ru) | 2013-03-27 |
JP5863196B2 (ja) | 2016-02-16 |
JP2014076994A (ja) | 2014-05-01 |
US20140066436A1 (en) | 2014-03-06 |
HK1187895A1 (zh) | 2014-04-17 |
JP2010540509A (ja) | 2010-12-24 |
US9493471B2 (en) | 2016-11-15 |
WO2009040556A1 (en) | 2009-04-02 |
ES2457394T3 (es) | 2014-04-25 |
RU2010116759A (ru) | 2011-11-10 |
CN101878216A (zh) | 2010-11-03 |
US20110046093A1 (en) | 2011-02-24 |
US20150344486A1 (en) | 2015-12-03 |
CA2700979A1 (en) | 2009-04-02 |
EP2610256A1 (en) | 2013-07-03 |
EP2610256B1 (en) | 2016-04-27 |
US9133199B2 (en) | 2015-09-15 |
PL2610256T3 (pl) | 2016-11-30 |
JP5410432B2 (ja) | 2014-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101878216B (zh) | 作为蛋白激酶抑制剂的嘧啶衍生物 | |
US10858373B2 (en) | Heterocyclic spiro compounds as MAGL inhibitors | |
US9751885B2 (en) | Cyclopropanamine compound and use thereof | |
JP2020164542A (ja) | Jak阻害剤である5−クロロ−2−ジフルオロメトキシフェニルピラゾロピリミジン化合物 | |
AU2016349089B2 (en) | Pyrimidine derivative and use thereof | |
CN107922403A (zh) | 作为胆碱能毒蕈碱m1受体的调节剂的2,3‑二氢‑4h‑1,3‑苯并噁嗪‑4‑酮衍生物 | |
KR20160038008A (ko) | 브로모도메인 억제제로서 신규 퀴나졸리논 | |
JP2020143118A (ja) | プロテインキナーゼ阻害剤である新規な2,3,5−置換チオフェン化合物 | |
US10975082B2 (en) | Inhibitor of FLT3 kinase and use thereof | |
CN102245612A (zh) | 新型三环衍生物或其药物可接受的盐、其制备方法和含有它们的药物组合物 | |
JP5508257B2 (ja) | アリールアミドピリミドン化合物 | |
JP5509070B2 (ja) | 神経変性疾患の治療のためのアリールアミドピリミドン誘導体 | |
MX2010013941A (es) | Derivados de pirimido [2-1-a] isoquinolina-4-ona sustituidos. | |
CN108368060B (zh) | 一类嘧啶类衍生物激酶抑制剂 | |
CN113993873B (zh) | 用于治疗癌症的egfr抑制剂 | |
CA2846187A1 (en) | Pyrimido-pyridazinone compounds and use thereof | |
JP2021519269A (ja) | ピペラジンアザスピロ誘導体 | |
US20060264431A1 (en) | P38 inhibitors and methods of use thereof | |
US10266535B2 (en) | Inhibitor of FLT3 kinase and use thereof | |
JP2004501153A (ja) | ファルネシルトランスフェラーゼ阻害性1,2−環付加キノリン鏡像異性体 | |
WO2024000401A1 (en) | 2-((1-(6-methyl-4-oxo-3,4-dihydroquinazolin-8-yl)ethyl)amino)benzoic acid derivatives and similar compounds as pi3k inhibitors for the treatment of e.g. cancer | |
JP2023521172A (ja) | キナーゼ阻害剤 | |
TW202024072A (zh) | 作為PI3Kβ抑制劑的1,5-二氮雜萘-4(1H)-酮衍生物 | |
EP3743414A1 (en) | Inhibitors of ras-effector protein interactions | |
JP2021506935A (ja) | ピリミジン誘導体系キナーゼ阻害剤類 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |